This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

The aim of this report is to systematically review the literature on treatment of heart failure by permanent cardiac resynchronisation therapy (CRT).

On the strength of evidence pertaining to safety, effectiveness and cost-effectiveness, MSAC recommends that public funding should be supported for the use of cardiac resynchronisation therapy in patients who have moderate to severe chronic heart failure (NYHA class III or IV) despite optimised medical therapy and who meet all of the following criteria-sinus rhythm, a left ventricular ejection fraction of less than or equal to 35% and a quasi-random signal (QRS) duration greater than or equal to 120ms.